体外肝代谢模型的优缺点及其应用

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (6): 688-694.

体外肝代谢模型的优缺点及其应用

李丹^1,2, 韩永龙^2,3, 余涛¹, 孟祥乐^1,2, 余奇², 王军², 郭澄²

¹上海中医药大学, 上海 201203;
²上海交通大学附属第六人民医院药剂科,上海 200233;
³大庆油田总医院临床药学科,大庆 163001,黑龙江

收稿日期:2011-04-14 修回日期:2011-05-19 发布日期:2011-07-25
通讯作者: 郭澄,男,博士,教授,主任药师,博士生导师,主要从事中药学与临床药理学研究。 Tel: 021-24058098 E-mail: gboss@sina.com
作者简介:李丹,女,在读博士研究生,主要从事中药药物代谢动力学研究。 Tel: 021-24058789 E-mail: lidandorren@126.com
基金资助:
国家自然科学基金(81072687);上海市药学会科研基金(2010-YY-01-03)

Advantages, disadvantages and applications of in vitro hepatic metabolic models

LI Dan^1,2, HAN Yong-long³, YU Tao¹, MENG Xiang-le^1,2, YU Qi², WANG Jun², GUO Cheng²

¹ Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
² The Sixth People's Hospital of Shanghai, Affiliated to Shanghai Jiaotong University, Shanghai 200233, China;
³ Department of Clinical Pharmacy, Daqing Oilfield General Hospital, Daqing 163001, Heilongjiang, China

Received:2011-04-14 Revised:2011-05-19 Published:2011-07-25

摘要/Abstract

摘要： 在所有参与药物生物转化的器官中,肝脏是最主要的场所。药物在肝脏或者肝外的代谢是药物消除的一种主要方式。由于药物在肝脏的代谢直接与其药理活性和毒性特征相关,进而影响药物在临床上的安全性和有效性,因此药物在肝脏的代谢是临床前新药研发过程中的一个非常重要的环节。近年来,相对于整体模型来说,体外研究模型以其快速、准确、高通量的优势在药物的肝脏生物转化研究中被药物研发的科学工作者广泛使用。目前常用的体外研究模型包括重组酶、微粒体、胞质溶胶、肝脏S9(S9)、细胞株、转基因细胞株、原代肝细胞、干细胞诱导分化的肝细胞、精密肝切片和肝脏灌流。笔者将对这些方法进行详细的概述,并对各自的优缺点进行比较并阐述其具体应用方向,方便研究人员选择合适可行的代谢模型,研究药物在肝脏中可能的生物转化模式,最终对药物在人体内的消除方式作出科学的预测。

关键词: 体外肝代谢模型, 优缺点, 应用, 药物生物转化

Abstract: The liver is the predominant organ participating metabolism of xenobiotics.Generally, drugs will be mainly eliminated from the body by the way of metabolism.Drug biotransformation is one of the most important events that affect the overall pharmacologic and toxic profile and the subsequent therapeutic and safety index.Hence, hepatic metabolism research is a key step in the preclinical drug discovery and development process.For this purpose, in vitro approaches using various hepatic metabolism models, with the merits of rapidness, accuracy, high throughput have been gaining increasing popularity in the academic and pharmaceutical fields.The presently used in vitro models includes recombinant enzymes, microsomes, cytosol, S9 fraction, cell lines, transgenic cell lines, primary hepatocytes, stem cell derived hepatic cell, precise liver slices and perfused liver.This review will describe the advantages, disadvantages and the applications of these in vitro models with the purpose of facilitating researchers to choose appropriate models to make reasonable evaluation of in vitro metablism and study the possible drug biotransformation model in liver,and finally to predict drug elimination mode in vivo scientifically.

Key words: In vitro hepatic metabolic model, Advantage and disadvantage, Application, Drug biotransformation

中图分类号:

R969.1

李丹, 韩永龙, 余涛, 孟祥乐, 余奇, 王军, 郭澄. 体外肝代谢模型的优缺点及其应用[J]. 中国临床药理学与治疗学, 2011, 16(6): 688-694.

LI Dan, HAN Yong-long, YU Tao, MENG Xiang-le, YU Qi, WANG Jun, GUO Cheng. Advantages, disadvantages and applications of in vitro hepatic metabolic models[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(6): 688-694.

参考文献

[1] Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects[J]. Am Fam Physician, 2007, 76(3): 391-396.
[2] Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity[J]. AAPS J, 2006, 8(1): E101-111.
[3] Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects[J]. Am Fam Physician, 2007, 76(3): 391.
[4] Kedderis GL, Lipscomb JC. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment[J]. Toxicol Ind Health, 2001, 17(5/6/7/8/9/10): 315-321.
[5] Friedberg F, Wolf CR. Merits and limitations of recombinant models for the study of human P450 mediated drug metabolism and toxicity : Am intralaboratory comparison[J]. Drug Metab Rev, 1999, 31 (2): 523-544.
[6] Parikh A, Gillam EM, Guengerich FP. Drug metabolism by escherichis coli expressing human cytochromes P450[J]. Nat Biotechnol, 1997, 15 (8): 784-788.
[7] Pelkonen O, Kaltiala EH, Larmi TK, et al. Cytochrome P-450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes[J]. Chem Biol Interact, 1974, 9(3): 205-216.
[8] Araya Z, Wikvall K. 6-alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes[J].
[9] Sheweita SA, Tilmisany AK. Cancer and phase II drug-metabolizing enzymes[J]. Curr Drug Metab, 2003, 4(1): 45-58.
[10] Guyomard C, Chesne C, Meunier B, et al. Primary culture of adult rat hepatocytes after 48-hour preservation of the liver with cold UW solution[J]. Hepatology, 1990,12(6): 1329-1336.
[11] Block GD, Locker J, Bowen WC, et al. Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium[J]. J Cell Biol, 1996, 132(6):1133-1149.
[12] Milosevic N, Schawalder H, Maier P. Kupffer cell-mediated differential down-regulation of cytochrome P450 metabolism in rat hepatocytes[J]. Eur J Pharmacol, 1999, 368(1): 75-87.
[13] Bayliss MK, Bell JA, Jenner WN, et al. Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man[J]. Xenobiotica, 1999, 29(3): 253-268.
[14] Sahi J, Grepper S, Smith C. Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery[J]. Curr Drug Discov Technol, 2010, 7(3):188-198.
[15] Grime K, Ferguson DD, Riley RJ. The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches[J]. Curr Drug Metab, 2010, 11(10): 870-885.
[16] Fardel O, Morel F, Raranasavanh D, et al. Expression of drug metabolizing enzymes in human Hep G₂ hepatoma cells[J]. Cell Mol Aspects Cirrhosis, 1992, 216:327-330.
[17] Gómez-Lechón MJ, Donato T, Jover R, et al. Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2[J]. Eur J Biochem, 2001, 268(5):1448-1459.
[18] Almar MM, Dierickx PJ. In vitro interaction of mercury, copper (II) and cadmium with human glutathione transferase pi[J]. Res Commun Chem Pathol Pharmacol, 1990, 69(1): 99-102.
[19] Guo L, Dial S, Shi L, et al. Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes[J]. Drug Metab Dispos, 2011, 39(3): 528-538.
[20] Donato MT, Lahoz A, Castell JV, et al. Cell lines: a tool for in vitro drug metabolism studies[J]. Curr Drug Metab, 2008, 9(1): 1-11.
[21] Touboul T, Hannan NR, Corbineau S, et al. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development[J]. Hepatology, 2010, 51(5):1754-1765.
[22] Sullivan GJ, Hay DC, Park IH, et al. Generation of functional human hepatic endoderm from human induced pluripotent stem cells[J]. Hepatology, 2010, 51(1): 329-335.
[23] Skare JA, Hewitt NJ, Doyle E, et al. Metabolite screening of aromatic amine hair dyes using in vitro hepatic models[J]. Xenobiotica, 2009, 39(11): 811-825.
[24] Jia L, Liu X. The conduct of drug metabolism studies considered good practice (II): in vitro experiments[J]. Curr Drug Metab, 2007, 8(8):822-829.